Market Outlook
By 2035, the U.S. Hospital-at-Home Devices Market is projected to reach approximately USD 7.66 billion, expanding at a 12.40% CAGR during 2026–2035. The market is estimated at USD 2.38 billion in 2025, following rapid development from approximately USD 1.08 billion in 2021, USD 1.31 billion in 2022, USD 1.61 billion in 2023, and USD 1.97 billion in 2024. Values in this report are expressed in USD billions.
The market definition covers medical devices and device-integrated hardware deployed to deliver inpatient-equivalent, high-acuity, transitional, or closely supervised clinical care in a patient’s residence. It includes multiparameter monitors, wearable biosensors, connected blood pressure and pulse-oximetry systems, portable ECG devices, infusion pumps, oxygen and respiratory-support equipment, point-of-care diagnostic devices, connected scales, glucose-management devices, portable imaging and auscultation technologies, safety systems, and other clinically managed equipment used within hospital-at-home programs. Software-only platforms, general telehealth services, home health labor, pharmaceuticals, and nonmedical consumer wellness devices are excluded except where the medical-device hardware component is embedded in a bundled solution.
The market’s strategic significance is considerably larger than its current revenue base. Hospital-at-home is evolving from a capacity-relief model created during the COVID-19 period into a permanent alternative site of acute care. Approximately 400 U.S. hospitals across 39 states had entered the federal Acute Hospital Care at Home pathway by 2025, demonstrating that hospital-level home care had moved beyond isolated academic pilots. CMS experience had already covered tens of thousands of acute-care episodes, while participating hospitals were treating patients with conditions such as congestive heart failure, pneumonia, COPD exacerbations, cellulitis, urinary infections, and other medically appropriate acute conditions.
A critical catalyst for the forecast is increased federal reimbursement visibility. The Acute Hospital Care at Home framework has subsequently received legislative authorization extending relevant flexibilities through September 30, 2030. This creates a substantially longer investment horizon for health systems considering command centers, enterprise remote monitoring, home infusion infrastructure, logistics networks, and standardized device kits. What had previously been difficult to justify as a short-duration pilot can increasingly be evaluated as a multi-year capital and clinical transformation program.
Device economics are also becoming more attractive. A hospital-at-home episode may require fewer fixed physical assets than a conventional inpatient stay, but it shifts a larger proportion of clinical dependence onto compact, connected and reliable medical technology. Instead of central nursing-station monitors and permanently installed hospital infrastructure, equipment must travel with the patient, connect reliably from variable residential environments, transmit actionable data to a command center, and be simple enough for patients, caregivers or mobile clinicians to use safely.
Consequently, manufacturers are competing not only on measurement accuracy but on connectivity reliability, battery life, cybersecurity, logistics readiness, interoperability, alarm management, ease of disinfection, patient usability, remote configuration and integration with hospital electronic health records.
The historical market expansion from USD 1.08 billion in 2021 to USD 2.38 billion in 2025 was driven by CMS waiver adoption, health-system experimentation with virtual wards, expansion of remote patient monitoring, home infusion capability, connected respiratory care, and greater confidence in managing selected acute patients outside hospital walls. From 2026 onward, growth is expected to become less pilot-dependent and increasingly tied to enterprise deployment, replacement cycles, standardized home-care kits and expansion into higher-acuity patient populations.
Introduction
According to the U.S. Hospital-at-Home Devices Market Report, the emerging hospital-at-home ecosystem represents one of the clearest examples of medical technology changing the physical location of care rather than merely improving an existing hospital procedure.
Hospital-at-home differs fundamentally from traditional home health. Eligible patients require an acute inpatient level of medical management but receive that care in a residential environment supported by physician oversight, nursing care, remote clinical monitoring, diagnostics, medication administration, escalation protocols and rapid-response capabilities. This makes the model considerably more device-intensive than routine home health.
The addressable hospital ecosystem is substantial. The United States has more than 6,000 hospitals, approximately 900,000 staffed hospital beds, and more than 34 million annual hospital admissions. Only a relatively small proportion of these admissions must migrate to hospital-at-home programs for the device opportunity to expand significantly.
Hospital-at-home is particularly attractive where hospitals face emergency-department boarding, inpatient bed constraints, seasonal capacity pressure, nursing shortages, rising construction costs or a strategic requirement to expand capacity without building another physical bed tower. A virtual bed supported by connected devices can create capacity without requiring the same real-estate footprint as incremental inpatient beds.
Demographics reinforce the opportunity. The U.S. population aged 65 years and older reached approximately 61.2 million in 2024, equivalent to roughly 18% of the national population. Older adults are disproportionately represented among patients with heart failure, COPD, diabetes, renal disease, infections and multimorbidity—the same categories that generate repeated acute hospital utilization.
Chronic disease also creates a large clinically eligible population. Recent U.S. data indicate that more than three-quarters of adults report at least one major chronic condition and over half report multiple chronic conditions. Among adults aged 65 and older, the prevalence of multiple chronic conditions is substantially higher. These patients generate recurring opportunities for early deterioration detection, acute stabilization at home and post-discharge monitoring.
The hospital-at-home device opportunity is therefore broader than a collection of remote monitoring products. It includes an interconnected clinical infrastructure. A typical high-acuity home episode can require a multiparameter monitor, blood-pressure measurement, pulse oximetry, temperature monitoring, ECG capability, connected weight measurement, oxygen equipment, IV infusion, medication-delivery devices, point-of-care testing, digital stethoscopy, telehealth peripherals and escalation communication equipment.
Procurement also differs from traditional home medical equipment. Hospital buyers increasingly evaluate standardized device packages across an entire care pathway. Decisions involve clinical engineering, nursing leadership, physicians, information technology, cybersecurity, procurement, value-analysis committees, digital health teams and hospital-at-home program executives.
Vendors that successfully address these multiple stakeholders can transition from supplying individual devices to becoming strategic infrastructure partners.
From 2026 through 2035, the market is expected to shift from remote monitoring as an isolated capability toward integrated home-acuity management. The strongest products will be those that make the home operationally resemble an extension of the hospital without making patients feel that they are living inside an intensive-care environment.
Key Market Drivers: What’s Fueling the U.S. Hospital-at-Home Devices Market Boom?
The most important structural driver is the increasing institutionalization of hospital-at-home care. The federal Acute Hospital Care at Home initiative created a credible reimbursement and regulatory pathway for Medicare-certified hospitals to move qualifying inpatient-level care into patients’ homes. By 2025, approximately 400 hospitals across 39 states had received authorization to participate, establishing a meaningful national installed base.
The extension of the federal pathway through September 2030 materially improves the investment case. Hospital boards and capital committees can evaluate connected monitoring platforms, device fleets and home-care logistics over several years rather than treating them as temporary emergency infrastructure.
A second driver is hospital capacity economics. Adding conventional beds requires expensive construction, staffing, utilities and fixed clinical infrastructure. Hospital-at-home does not eliminate care costs, but it can convert part of capacity expansion from fixed physical infrastructure into distributed clinical technology and mobile care operations.
This is important in rapidly growing metropolitan markets where inpatient expansion can require hundreds of millions of dollars and multi-year construction timelines.
A third driver is evidence supporting the economics of appropriate hospital-at-home care. Earlier randomized experience examined by U.S. policymakers found risk-adjusted acute-care provider costs approximately 19% lower for hospital-at-home participants than for comparable brick-and-mortar care, with the difference reaching approximately 25% when the subsequent 30-day period was included. Hospital-at-home programs have also demonstrated favorable results in readmission, functional activity and patient experience for appropriately selected populations.
These economics create a strong value proposition for technologies capable of safely replacing portions of centralized inpatient monitoring.
A fourth driver is the aging U.S. population. Older patients often experience mobility limitations, delirium risk, sleep disruption, falls or functional decline during institutional hospitalization. Appropriate home-based acute care can preserve familiar surroundings while still providing medical supervision. This population creates demand for unobtrusive monitoring, fall detection, wearable biosensors, medication delivery, respiratory equipment and simple diagnostic devices.
A fifth driver is multimorbidity. Approximately 194 million U.S. adults reported at least one selected chronic condition in 2023, while roughly 130 million reported two or more. For adults aged 65 and older, multiple chronic conditions affect a large majority of the population. Heart failure combined with renal dysfunction, COPD combined with cardiovascular disease, or diabetes complicated by infection can require continuous physiological surveillance rather than occasional telehealth interaction.
Hospital-at-home technology therefore needs to evolve from single-parameter consumer monitoring toward multi-condition clinical surveillance.
A sixth driver is the growing clinical acceptability of remote patient monitoring. Continuous and intermittent device-based monitoring can transmit oxygen saturation, respiratory rate, heart rate, rhythm information, temperature, blood pressure, weight and other parameters into centralized dashboards. Clinical teams can identify changes before patients experience obvious deterioration.
The value of these devices rises sharply when algorithms help prioritize patients instead of generating indiscriminate alarms. Alarm fatigue can otherwise reproduce one of the major workflow problems already experienced inside hospitals.
A seventh driver is the expansion of home infusion and medication delivery. Many acute-care pathways depend on IV antibiotics, diuretics, hydration, biologics or other infused therapies. Portable infusion pumps and connected drug-delivery systems enable treatment that historically required hospital or infusion-center infrastructure.
Hospitals increasingly evaluate infusion-device fleets together with pharmacy logistics, medication compounding, nursing visits and adverse-event escalation.
An eighth driver is health-system consolidation. Large integrated delivery networks can standardize hospital-at-home technology across several hospitals and metropolitan markets. Enterprise procurement increases purchasing volume and makes interoperability, centralized device management and standardization more important than individual-device specifications.
The winning vendor may not necessarily offer the lowest-priced monitor. It may offer the lowest operational burden across thousands of patient-days.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation in the U.S. Hospital-at-Home Devices Market is moving toward devices designed specifically for distributed acute care rather than hospital products merely repackaged for residential use.
Continuous wearable monitoring is one of the most important areas of development. Adhesive biosensors and lightweight wearable devices can capture heart rate, respiratory rate, skin temperature, activity, posture and other signals without tethering a patient to a bedside monitor. This makes continuous surveillance more compatible with normal movement around the home.
The next technological objective is clinically meaningful deterioration prediction. Raw physiological data have limited value if nurses must manually review every measurement. Advanced systems are increasingly designed to identify trend deviations, combine several parameters, prioritize patient risk and escalate actionable changes.
Portable diagnostics represent another important frontier. Digital stethoscopes, handheld ECG devices, connected otoscopes, point-of-care blood testing, portable ultrasound and other compact diagnostic technologies can increasingly bring elements of the hospital examination into the home. These products reduce the number of situations in which a patient must return to an emergency department purely because diagnostic information cannot be obtained remotely.
Respiratory technology is also becoming more home-acuity oriented. Connected oxygen concentrators, pulse oximeters, CPAP/BiPAP systems, portable ventilatory support and respiratory monitoring are especially important for COPD, pneumonia and other pulmonary conditions.
COPD alone remains a major clinical burden. Diagnosed COPD affected approximately 3.8% of U.S. adults in recent national data and exceeded 10% among people aged 75 and older. The disease is therefore highly relevant to hospital-at-home respiratory-device demand.
Infusion-system innovation centers on portability, safety and connectivity. Pumps used outside the hospital must be resistant to programming errors, easy to transport and appropriate for environments without constant bedside nursing presence. Remote status visibility and drug-library functionality can become strategic differentiators.
Another emerging focus is the physical design of home-use medical technology. FDA’s Home as a Health Care Hub initiative has explicitly highlighted the challenge created when patients must manage multiple disconnected devices inside housing environments that were never designed as clinical spaces.
This creates opportunities for smaller footprints, fewer cables, intuitive interfaces, automated connectivity and integrated device kits.
Cybersecurity is simultaneously becoming a purchasing requirement. Hospital-at-home programs can deploy hospital-managed endpoints across hundreds or thousands of private residences. Each connected device potentially becomes part of the health system’s digital attack surface.
Health systems increasingly expect encryption, secure authentication, remote patching, device inventory management and clearly documented cybersecurity practices.
Finally, manufacturers are redesigning commercial models. Traditional capital purchase is only one option. Leasing, device-as-a-service, per-patient-day pricing, program bundles and managed device logistics are becoming more relevant because hospitals may want technology capacity to scale with census rather than own an underutilized fleet.
Segmentation Insights
The U.S. Hospital-at-Home Devices Market is segmented on the basis of device type, clinical application, care model, end user/procurement channel, and region.
By Device Type
Multiparameter and Continuous Patient Monitoring Devices
Multiparameter and continuous monitoring systems represent the largest strategic device category. This segment includes connected blood-pressure monitors, pulse oximeters, wearable biosensors, ECG monitors, thermometers, respiratory-rate monitors, connected scales and integrated vital-sign platforms.
These products form the physiological surveillance layer of hospital-at-home programs. Unlike routine consumer monitoring, hospital-at-home monitoring requires clinical-grade performance, defined escalation protocols, dependable connectivity and workflow integration.
The category is expected to record strong growth through 2035 as hospitals move from pilot programs that use individual Bluetooth peripherals toward standardized multi-parameter kits and wearable continuous monitoring.
Therapeutic and Drug-Delivery Devices
This category includes portable infusion pumps, ambulatory drug-delivery systems, enteral feeding equipment, medication-administration technologies, connected injectors and related acute-care delivery equipment.
Infusion technology is especially important because IV antibiotics, diuresis, hydration and selected complex therapies can determine whether a patient is clinically suitable for hospital-at-home treatment.
Adoption is linked closely to home infusion pharmacy capability and mobile nursing coverage. Manufacturers with connected pump platforms, strong drug libraries and established hospital relationships are positioned favorably.
Respiratory Support and Oxygen Therapy Devices
Respiratory equipment includes oxygen concentrators, portable oxygen systems, CPAP, BiPAP, nebulization equipment, respiratory monitors and selected non-invasive ventilatory support technologies.
Pneumonia and COPD exacerbations are among the clinically relevant conditions for acute home management, making respiratory technology a foundational component of the market.
Demand is particularly strong where systems integrate oxygen saturation and respiratory data into command-center workflows rather than operating as isolated durable medical equipment.
Point-of-Care Diagnostic and Examination Devices
Point-of-care devices include handheld ECG equipment, digital stethoscopes, blood chemistry and hematology testing systems, portable ultrasound, connected examination peripherals and other diagnostic hardware that reduces reliance on facility-based testing.
This category is expected to grow faster than basic spot-check monitoring because diagnostic limitations are an important barrier to expanding the clinical complexity of patients treated at home.
As hospitals attempt to treat higher-acuity populations, the home must support more than vital-sign collection.
Mobility, Safety and Connected Support Devices
This category includes fall-detection systems, mobility-support equipment, smart medication dispensers, emergency-response devices and selected connected environmental or patient-safety hardware.
Revenue per device can be lower than advanced monitoring and infusion equipment, but these technologies address a critical operational challenge: hospital-at-home programs must evaluate not only medical stability but whether a residence is safe enough to function as a temporary site of inpatient care.
By Clinical Application
Cardiovascular and Heart Failure Care
Cardiovascular conditions represent one of the most attractive hospital-at-home applications. Heart failure patients frequently require daily weight measurement, blood pressure monitoring, pulse oximetry, ECG evaluation, medication adjustment and sometimes IV diuresis.
The economic incentive is significant because heart failure generates recurrent emergency visits and readmissions. Connected scales, wearable monitors and home infusion systems allow health systems to intervene before a patient reaches severe decompensation.
Respiratory Disease Management
Respiratory applications include COPD exacerbation, selected pneumonia cases and other acute pulmonary conditions appropriate for home management.
Devices commonly include pulse oximeters, oxygen systems, respiratory monitors, nebulizers and non-invasive ventilation equipment. Recent national data place diagnosed COPD at approximately 3.8% of U.S. adults, increasing substantially among older age groups.
The respiratory segment benefits from established home oxygen infrastructure and a large DME distribution ecosystem.
Infectious Disease and Acute Medical Care
Hospital-at-home programs increasingly manage cellulitis, urinary tract infections, selected pneumonia cases and other acute medical diagnoses requiring close monitoring or IV treatment but not immediate procedural intervention.
This application supports demand for infusion pumps, temperature monitoring, point-of-care diagnostics and connected vital-sign systems.
The segment is operationally attractive because many patients have relatively predictable treatment pathways once acute instability has been excluded.
Post-Surgical and Orthopedic Recovery
Selected surgical patients can transition home earlier when hospitals have adequate monitoring, wound assessment, mobility support and escalation capability.
The device opportunity includes vital-sign monitors, mobility equipment, connected rehabilitation technologies, wound-management devices and selected pain-management systems.
This segment is likely to become more important as health systems combine enhanced recovery after surgery protocols with virtual inpatient and post-acute pathways.
Complex Chronic, Metabolic, Renal and Oncology Care
Diabetes, renal disease and medically complex oncology patients create an increasingly sophisticated home-device opportunity.
Continuous glucose monitoring, insulin delivery, connected blood pressure systems, weight monitoring, infusion equipment and point-of-care testing can support acute episodes layered on chronic disease.
This segment also aligns with FDA’s broader focus on designing medical devices that function effectively inside diverse residential environments.
By Care Model
Acute Inpatient Substitution
Acute inpatient substitution represents the core hospital-at-home model. Patients who would otherwise occupy an inpatient bed receive equivalent hospital responsibility and clinical oversight in the home.
This model produces the highest device intensity because programs require comprehensive monitoring, treatment, communications and rapid escalation.
Early Supported Discharge
Early supported discharge moves clinically improving patients from the hospital into the home sooner while maintaining elevated monitoring and treatment intensity.
Device requirements are generally lower than full admission substitution, but patient volumes can be considerably larger. Hospitals value this model because freeing a physical bed even one day earlier can improve inpatient throughput.
High-Acuity Chronic Exacerbation Management
Heart failure, COPD and other chronic diseases generate episodes that may require near-hospital monitoring without immediate invasive intervention.
Connected physiological monitoring and home therapeutics allow health systems to establish escalation pathways that sit between outpatient RPM and conventional admission.
This segment has significant long-term potential because chronic diseases create recurring utilization rather than one-time episodes.
Post-Operative Virtual Wards
Virtual wards provide structured surveillance during the period after surgery when clinical deterioration, wound complications or medication-related issues can trigger readmission.
The model supports wearable monitoring, digital wound assessment, mobility tracking and telehealth examination devices.
Expansion will depend on surgical-service-line economics and the willingness of surgeons to incorporate remote monitoring into standard postoperative pathways.
Hybrid Hospital-at-Home Programs
Hybrid models combine remote command centers, scheduled mobile clinical visits, device-based continuous monitoring, home infusion, diagnostic services and emergency-response capability.
Hybrid care is likely to become the dominant operational model because hospital-level care cannot rely exclusively on virtual visits or exclusively on in-person staffing.
The technology opportunity therefore increasingly centers on connecting physical devices to mobile and centralized clinical workflows.
By End User and Procurement Channel
Hospitals and Integrated Health Systems
Hospitals and integrated delivery networks are the dominant buyers. They control acute admission pathways, clinical governance, Medicare billing and escalation back to brick-and-mortar facilities.
Large systems increasingly seek enterprise platforms that can standardize device fleets across several hospitals. Purchasing decisions emphasize clinical evidence, cybersecurity, interoperability, service reliability and total cost per episode.
Hospital-at-Home Enablement and Technology Companies
Specialized hospital-at-home enablement companies can aggregate device demand on behalf of health-system customers. Some provide remote command-center capabilities, clinical logistics, monitoring infrastructure or complete operating models.
For device manufacturers, these companies represent valuable channels because one enablement relationship can create access to several hospital programs.
Home Infusion and Specialty Pharmacy Providers
Home infusion organizations are strategically important purchasers of pumps, medication-delivery systems and related equipment.
As hospital-at-home programs move into conditions requiring IV medications, integration between the hospital, pharmacy, nursing operation and pump fleet becomes essential.
Durable Medical Equipment and Respiratory Providers
DME companies supply oxygen equipment, respiratory products, mobility hardware and other home-use technologies. Their distribution networks can solve an operational problem that hospitals are not traditionally designed to manage: delivering and retrieving equipment from thousands of residential locations.
Home Health, Mobile Clinical and Risk-Bearing Care Organizations
Home health agencies, mobile medical groups, Medicare Advantage organizations, accountable care organizations and other risk-bearing providers are becoming increasingly relevant participants.
Their interest is strongest when avoiding an inpatient stay or reducing downstream utilization creates economic value beyond the individual device sale.
Regional Insights: Where the Market is Growing Fastest
Regional performance in the U.S. Hospital-at-Home Devices Market depends on population growth, Medicare concentration, chronic disease burden, hospital-system consolidation, state reimbursement policy, digital-health adoption, home-infusion infrastructure and geographic feasibility of rapid in-home response.
The South represents the largest regional market in 2025 at approximately USD 0.83 billion, followed by the West at USD 0.60 billion, the Northeast at USD 0.55 billion, and the Midwest at USD 0.40 billion.
The West is expected to record the fastest regional growth through 2035, while the South should remain the largest absolute opportunity.
South
The South accounts for approximately USD 0.83 billion in 2025, representing roughly 35% of U.S. hospital-at-home device revenue. The region is projected to approach USD 2.59 billion by 2035, representing growth of approximately 12.0% annually.
The region includes Texas, Florida, Virginia, North Carolina, Georgia, Tennessee, Maryland, South Carolina, Alabama, Kentucky, Louisiana, Mississippi, Arkansas, Oklahoma and West Virginia, among other Southern markets.
Texas is one of the country’s largest hospital-at-home opportunities because of its population scale, large integrated health systems, major metropolitan markets and combination of Medicare and commercially insured patients. Houston, Dallas–Fort Worth, Austin and San Antonio provide dense service areas where mobile clinical teams and equipment logistics can operate efficiently.
Texas also provides significant demand for cardiovascular, diabetes, respiratory and renal monitoring technologies.
Florida is equally important but for a different reason. Its unusually large older population supports strong demand for hospital-at-home models addressing heart failure, COPD, infection and multimorbidity. Home respiratory equipment, cardiac monitoring and fall-risk technologies have particularly strong relevance.
North Carolina is developing into another important market because of sophisticated academic systems and rapidly expanding population centers. The state also had an established Medicaid pathway for hospital-at-home reimbursement by 2025, improving the potential payer mix beyond Medicare.
Georgia, Tennessee and Virginia benefit from expanding health systems, major metro populations and strong regional referral structures. Atlanta, Nashville, Northern Virginia and the Richmond corridor provide particularly attractive geographic concentrations for distributed care.
Arkansas, Oklahoma and South Carolina are notable because state Medicaid policy had already moved toward paying for hospital-at-home services for fee-for-service beneficiaries by 2025. Such policies can eventually broaden the commercial justification for device infrastructure.
Alabama, Mississippi, Louisiana, Kentucky and West Virginia have comparatively high chronic disease burdens. These markets could benefit significantly from home-based acute care but face challenges related to broadband access, rural distance, workforce availability and 30-minute emergency-response requirements.
These constraints create demand for devices with cellular redundancy, longer battery life and simplified installation.
The South’s long-term advantage is scale. Population growth, older demographics and large metropolitan hospital systems should keep it the largest regional market even as faster technology adoption allows the West to gain share.
West
The West represents approximately USD 0.60 billion in 2025 and is expected to reach about USD 2.24 billion by 2035, producing an estimated 14.2% CAGR, the fastest among the four U.S. regions.
The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.
California is the dominant Western market. Its importance comes from population scale, advanced integrated care networks, technology adoption and a strong digital-health ecosystem. Large California health systems can combine home monitoring with integrated electronic records, virtual-care teams, pharmacy networks and value-based contracting.
California is particularly attractive for wearable monitoring, connected diagnostics and device-as-a-service models.
Arizona is positioned for above-average growth due to rapid population expansion and a large older-adult population. It was also among the states supporting Medicaid fee-for-service hospital-at-home payment by 2025. Phoenix and Tucson offer sufficiently dense urban populations for mobile acute-care logistics.
Washington and Oregon have strong experience with integrated healthcare delivery and connected care. Oregon’s Medicaid participation adds another pathway for home-based acute models.
Colorado and Utah combine population growth with sophisticated health systems and relatively high acceptance of digital care. Utah was notable as one of the original locations participating in federal hospital-at-home expansion.
Nevada presents strong growth potential, particularly around Las Vegas, where hospital capacity pressure and population growth can strengthen the business case for virtual beds.
New Mexico offers a different model. Presbyterian Healthcare Services was among the early U.S. organizations associated with hospital-at-home implementation, giving the state strategic significance despite its relatively small population.
Rural Western states highlight one of the market’s major limitations. Large travel distances can complicate rapid clinical response, specimen transportation and equipment replacement. Vendors capable of minimizing the need for technician visits through remote configuration and self-installing devices will have an advantage.
Northeast
The Northeast accounts for approximately USD 0.55 billion in 2025 and is forecast to approach USD 1.63 billion by 2035, representing approximately 11.5% annual growth.
The region includes New York, Massachusetts, Pennsylvania, New Jersey, Connecticut, Maine, Vermont, New Hampshire, Rhode Island and Delaware.
The Northeast is disproportionately important to hospital-at-home innovation because several early academic and clinical programs were developed in the region.
Massachusetts is particularly influential. Brigham and Women’s Hospital and Massachusetts General Hospital were among the original health systems authorized when CMS launched the Acute Hospital Care at Home initiative in 2020. The state’s concentration of academic medicine and biomedical innovation supports early evaluation of monitoring systems and diagnostic technologies.
New York is one of the largest state-level markets. Mount Sinai was also among the earliest nationally recognized hospital-at-home operators. New York City’s density creates favorable mobile logistics economics because large patient populations can be covered without the travel distances encountered in rural regions.
New York also supported Medicaid fee-for-service hospital-at-home reimbursement by 2025.
New Jersey and Pennsylvania provide sizable patient populations and dense hospital networks. New Jersey was another state where Medicaid reimbursement supported the model, creating additional payer diversification.
Connecticut and the smaller New England states represent more mature healthcare markets with strong Medicare exposure. Their challenge is less clinical acceptance than achieving adequate patient density outside major metro areas.
Procurement in the Northeast is typically evidence-intensive. Academic and tertiary systems expect rigorous clinical validation, cybersecurity documentation, health-economic evidence and EHR integration.
Consequently, the region can serve as an important reference market. Technologies adopted by Boston and New York academic institutions can influence purchasing decisions nationally.
Midwest
The Midwest represents approximately USD 0.40 billion in 2025 and is forecast to reach approximately USD 1.20 billion by 2035, reflecting growth of around 11.5% per year.
The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.
Illinois provides the largest metropolitan opportunity through Chicago, where major integrated health systems can create sufficient patient density for hospital-at-home operations.
Ohio has a large hospital infrastructure and strong specialist networks. Cleveland, Columbus and Cincinnati are particularly attractive markets for connected monitoring and acute home programs.
Michigan combines significant chronic disease burden with large integrated hospital systems. It was also among the states with Medicaid fee-for-service support for hospital-at-home care by 2025.
Minnesota has unusual strategic relevance because of its medical-device ecosystem. The state’s concentration of medtech capabilities, payer sophistication and integrated provider organizations can support early deployment of advanced monitoring and therapeutic technologies.
Iowa has historical significance because UnityPoint Health was among the first systems involved in the federal hospital-at-home expansion. This early operational experience can support continued regional adoption.
South Dakota had also established Medicaid payment for hospital-at-home care, illustrating that the model is not limited to highly urbanized states.
The Midwest’s principal challenge is geography. Large rural catchment areas can make rapid home response difficult. For manufacturers, however, this creates a clear design requirement: products need high reliability, remote troubleshooting, cellular connectivity and minimal need for field service.
The Midwest will remain smaller than the South or West but provides a durable market for hospitals seeking to extend coverage over broad service territories without replicating expensive facility infrastructure.
Key Market Players
The U.S. Hospital-at-Home Devices Competitive Landscape is fragmented because no single manufacturer currently owns the complete clinical hardware stack required for inpatient-equivalent home care.
Large medtech companies dominate monitoring, infusion, respiratory and chronic-disease hardware, while specialized digital-device companies compete in wearable monitoring, mobile diagnostics and connected examination.
Competition is increasingly shifting from product specifications toward ecosystem fit. Hospital systems prefer devices that can operate inside a common clinical workflow, integrate with command-center software, transmit structured information into EHRs, support remote fleet management and remain simple for patients.
Some of the key players relevant to the U.S. Hospital-at-Home Devices industry include:
- Philips
- GE HealthCare
- Medtronic
- Abbott Laboratories
- Baxter International
- Masimo
- ResMed
- Becton, Dickinson and Company
- B. Braun
- ICU Medical
- Dexcom
- Insulet Corporation
- iRhythm Technologies
- Boston Scientific Corporation
- ZOLL Medical
- BioIntelliSense
- VitalConnect
- Current Health / Best Buy Health
- TytoCare
- AliveCor
- Eko Health
- Withings Health Solutions
- Fisher & Paykel Healthcare
- OMRON Healthcare
Philips, GE HealthCare, Medtronic, Baxter and Masimo have advantages stemming from established hospital relationships and broad monitoring or therapeutic portfolios.
Abbott, Dexcom and Insulet are strategically relevant as diabetes and cardiometabolic management become integrated into more complex home-care pathways.
Becton Dickinson, B. Braun and ICU Medical participate strongly in infusion and medication delivery.
ResMed and Fisher & Paykel Healthcare address respiratory care, while ZOLL and iRhythm support cardiac monitoring and rhythm-related applications.
BioIntelliSense and VitalConnect represent the transition toward lightweight continuous biosensing.
TytoCare, AliveCor and Eko Health extend diagnostic examination into the home through connected examination, ECG and digital auscultation technologies.
Current Health, operating within Best Buy Health, illustrates how the competitive landscape is expanding beyond traditional medtech into integrated monitoring, logistics and technology-enabled home-care infrastructure.
Over the forecast period, competitive advantage will increasingly depend on four capabilities: enterprise interoperability, clinical evidence, scalable device logistics and flexible commercial models.
Recent Developments
Recent developments indicate that hospital-at-home is entering a more durable U.S. commercialization phase.
In 2024, CMS reported that more than 31,000 patients had already received care through the Acute Hospital Care at Home initiative, with hundreds of hospitals participating across dozens of states. The scale provided the federal government with enough experience to evaluate quality, utilization and patient outcomes beyond individual institutional studies.
By 2025, approximately 400 hospitals across 39 states had obtained federal waivers to participate. The market therefore entered 2026 with a meaningful installed health-system base rather than a collection of experimental programs.
A major policy development occurred when federal legislation subsequently extended Acute Hospital Care at Home flexibilities through September 30, 2030. This is strategically important for the device industry because health systems can now evaluate infrastructure spending against a multi-year reimbursement runway.
Regulatory attention to home-use medical technology has also increased. The FDA launched its Home as a Health Care Hub initiative in 2024 to encourage medical technologies that function more effectively within real residential environments.
The initiative highlights interoperability, usability, housing constraints and the need to design medical devices as part of a coordinated home ecosystem instead of as isolated products.
The FDA further advanced this direction through its READI-Home: Reducing Readmissions through Device Innovation for the Home initiative. The program reinforces an emerging regulatory view that medical-device innovation can play a direct role in avoiding preventable hospital utilization.
Hospitals are simultaneously moving toward standardized equipment kits. Rather than assembling a different set of consumer-style peripherals for every patient, mature programs increasingly favor predefined configurations for heart failure, respiratory disease, infection and other clinical pathways.
The market is also moving toward continuous monitoring rather than simple scheduled vital-sign collection. Wearable biosensors capable of generating longitudinal trends may improve the ability of command-center nurses to identify deterioration between in-person visits.
Another development is the growing integration of logistics into technology contracts. Device suppliers increasingly need to address deployment, retrieval, cleaning, charging, replacement and inventory tracking. A clinically excellent device that cannot be delivered reliably to a patient’s home may have little value in a hospital-at-home operating model.
Conclusion
The U.S. Hospital-at-Home Devices Market Size & Share is positioned for significant expansion from approximately USD 2.38 billion in 2025 to USD 7.66 billion by 2035, representing an aggressive 12.40% CAGR during 2026–2035.
Historical market development from USD 1.08 billion in 2021 to USD 1.97 billion in 2024 reflected the transition from emergency pandemic-era experimentation to organized hospital-at-home infrastructure. The next phase will be driven by enterprise commercialization.
The market is supported by several structural forces that are unlikely to reverse: an aging population, high chronic disease prevalence, hospital bed pressure, nursing constraints, increasing acceptance of remote monitoring and growing demand to manage healthcare expenditure outside expensive institutional settings.
Federal policy has become considerably more supportive following extension of Acute Hospital Care at Home flexibilities through September 2030, providing health systems with greater certainty for multi-year investment.
Multiparameter monitoring and wearable biosensing will remain central to the market, but the largest incremental opportunity will increasingly come from technologies that allow hospitals to manage more clinically complex patients. Portable diagnostics, connected respiratory therapy, infusion systems, digital examination devices and integrated safety equipment will expand the clinical envelope of hospital-at-home care.
The competitive model will also change. Hospitals will move away from evaluating individual devices in isolation and toward assessing complete distributed-care infrastructure. A winning technology stack must deliver accurate measurement, reliable connectivity, cybersecurity, workflow integration, remote fleet management, patient usability and strong service support.
Regional opportunity will remain uneven. The South is expected to remain the largest market, supported by Texas, Florida, North Carolina, Georgia and other rapidly growing states. The West is projected to expand fastest, driven by California, Arizona, Washington, Oregon and digitally sophisticated health systems. The Northeast will continue to influence clinical standards and early adoption, particularly through Massachusetts and New York, while the Midwest will provide a durable market for remote monitoring and scalable distributed-care infrastructure.
For medtech manufacturers, investors, hospital executives and strategic suppliers, the essential question is no longer whether monitoring can technically occur in the home. The more valuable question is which devices can make a residential setting operationally safe enough, connected enough and clinically capable enough to replace an inpatient bed.
The companies that solve that problem will participate in one of the most important care-site migrations occurring in the U.S. medical device industry.
TABLE OF CONTENT
1. U.S. Hospital-at-Home Devices Market: Market Introduction & Context
1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Hospital-at-Home Medical Device Manufacturers
1.6.2. Remote Patient Monitoring and Connected Device Providers
1.6.3. Hospitals and Integrated Health Systems
1.6.4. Hospital-at-Home Enablement and Virtual Care Companies
1.6.5. Home Infusion and Specialty Pharmacy Providers
1.6.6. Durable Medical Equipment and Respiratory Care Providers
1.6.7. Home Health and Mobile Clinical Care Organizations
1.6.8. Group Purchasing Organizations and Medical Device Distributors
1.6.9. CMS, Commercial Payers, State Medicaid Programs and Regulators
1.6.10. Patients, Caregivers and Clinical Decision-Makers
What this section provides: This section establishes the market boundary, study scope, research methodology, assumptions, device ecosystem, and stakeholder structure used to measure and evaluate the U.S. Hospital-at-Home Devices Market.
2. U.S. Hospital-at-Home Devices Market: Executive Summary
2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Outlook
2.7.1. U.S. Market Size, 2021–2025
2.7.2. U.S. Market Forecast, 2026–2035
2.7.3. CAGR Analysis, 2026–2035
2.8. High-Growth Opportunity Areas
2.9. Leading Device Categories
2.10. Fastest-Growing Clinical Applications
2.11. Regional Opportunity Snapshot
2.12. Hospital-at-Home Adoption and Participation Snapshot
What this section provides: This section gives decision-makers an executive view of market size, historical development, forecast growth, hospital-at-home adoption, leading device categories, regional demand, and the highest-priority commercial opportunities.
3. U.S. Hospital-at-Home Devices Market: Market Dynamics & Outlook
3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of Acute Hospital Care at Home Programs
3.1.2. Increasing Hospital Capacity and Bed-Utilization Pressure
3.1.3. Aging U.S. Population and Growing Multimorbidity
3.1.4. Rising Adoption of Remote Patient Monitoring
3.1.5. Growth of Home Infusion and Ambulatory Drug Delivery
3.1.6. Increasing Demand for Hospital-Level Respiratory Care at Home
3.1.7. Expansion of Connected Point-of-Care Diagnostics
3.1.8. Pressure to Reduce Length of Stay and Avoidable Readmissions
3.1.9. Health-System Shift Toward Distributed Care Capacity
3.2. Restraints and Their Impact Analysis
3.2.1. Device Connectivity and Broadband Reliability Limitations
3.2.2. High Initial Program Infrastructure Costs
3.2.3. Patient Eligibility and Residential Suitability Constraints
3.2.4. Device Interoperability Challenges
3.2.5. Cybersecurity and Patient Data Protection Risks
3.2.6. Clinical Liability and Escalation Risk
3.2.7. Rural Logistics and Rapid-Response Limitations
3.3. Opportunities and Their Impact Analysis
3.3.1. Continuous Wearable Biosensor Deployment
3.3.2. AI-Assisted Deterioration Detection
3.3.3. Portable Diagnostic and Examination Technologies
3.3.4. Connected Infusion and Medication Delivery
3.3.5. Home-Based Respiratory Management
3.3.6. Device-as-a-Service and Per-Patient-Day Commercial Models
3.3.7. Standardized Hospital-at-Home Device Kits
3.3.8. Expansion into Higher-Acuity Clinical Pathways
3.3.9. Integration with EHR and Virtual Command Centers
3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Workflow Standardization
3.4.2. Device Logistics, Retrieval and Reprocessing
3.4.3. Alarm Fatigue and Remote Monitoring Workload
3.4.4. Nursing and Mobile Clinical Workforce Availability
3.4.5. Home Environment Variability
3.4.6. Reimbursement Sustainability
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Hospital-at-Home Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Inpatient Bed Substitution Economics
3.9. Cost-per-Episode and Device Utilization Analysis
3.10. Patient Selection and Clinical Escalation Framework
What this section provides: This section evaluates the clinical, operational, economic, reimbursement, and technology forces affecting hospital-at-home device adoption and helps clients assess market upside alongside implementation and commercialization risks.
4. U.S. Hospital-at-Home Devices Market: Market Environment & Industry Analysis
4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Hospital and Health-System Buyers
4.2.3. Bargaining Power of Device and Component Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Medical Device Manufacturing
4.4.2. Connectivity and Sensor Components
4.4.3. Hospital Procurement and GPO Contracting
4.4.4. Device Deployment and Last-Mile Logistics
4.4.5. Equipment Recovery, Cleaning and Reprocessing
4.5. Impact of Digitalization and Connected Acute Home Care
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework for Home-Use Medical Devices
4.8. CMS Acute Hospital Care at Home Framework
4.9. CMS Reimbursement and Coverage Landscape
4.10. State Medicaid Hospital-at-Home Reimbursement Landscape
4.11. Commercial Payer and Medicare Advantage Coverage Trends
4.12. FDA Home as a Health Care Hub Initiative
4.13. Medical Device Cybersecurity Requirements
4.14. Interoperability and EHR Integration Landscape
4.15. Import/Export Restrictions & Tariff Impact
4.16. Government Initiatives Supporting Home-Based Care
4.17. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.18. Hospital Value Analysis Committee Decision Framework
4.19. Device Fleet Management and Utilization Economics
What this section provides: This section gives clients a complete view of the regulatory, reimbursement, competitive, technological, supply-chain, cybersecurity, interoperability, and hospital-procurement environment influencing the U.S. Hospital-at-Home Devices Market.
5. U.S. Hospital-at-Home Devices Market – By Device Type
5.1. Overview
5.1.1. Segment Share Analysis, By Device Type, 2025 & 2035 (%)
5.1.2. Multiparameter and Continuous Patient Monitoring Devices
5.1.2.1. Multiparameter Vital Signs Monitors
5.1.2.2. Wearable Continuous Biosensors
5.1.2.3. Connected Blood Pressure Monitors
5.1.2.4. Pulse Oximeters
5.1.2.5. ECG and Cardiac Rhythm Monitoring Devices
5.1.2.6. Connected Thermometers
5.1.2.7. Respiratory Rate Monitoring Devices
5.1.2.8. Connected Weight Scales
5.1.3. Therapeutic and Drug-Delivery Devices
5.1.3.1. Ambulatory Infusion Pumps
5.1.3.2. Volumetric Infusion Pumps
5.1.3.3. Syringe Pumps
5.1.3.4. Enteral Feeding Pumps
5.1.3.5. Connected Medication Delivery Systems
5.1.3.6. Other Home-Based Therapeutic Devices
5.1.4. Respiratory Support and Oxygen Therapy Devices
5.1.4.1. Oxygen Concentrators
5.1.4.2. Portable Oxygen Systems
5.1.4.3. CPAP Devices
5.1.4.4. BiPAP Devices
5.1.4.5. Nebulizers
5.1.4.6. Non-Invasive Ventilatory Support Devices
5.1.4.7. Connected Respiratory Monitoring Systems
5.1.5. Point-of-Care Diagnostic and Examination Devices
5.1.5.1. Handheld ECG Devices
5.1.5.2. Digital Stethoscopes
5.1.5.3. Portable Ultrasound Systems
5.1.5.4. Point-of-Care Blood Testing Devices
5.1.5.5. Connected Examination Devices
5.1.5.6. Other Portable Diagnostic Devices
5.1.6. Mobility, Safety and Connected Support Devices
5.1.6.1. Fall Detection Devices
5.1.6.2. Emergency Response Systems
5.1.6.3. Smart Medication Dispensers
5.1.6.4. Mobility Support Devices
5.1.6.5. Connected Patient Safety Devices
5.1.6.6. Other Supporting Medical Equipment
What this section provides: This section identifies the hospital-at-home device categories expected to generate the largest revenue contribution and strongest growth, while showing how monitoring, respiratory, therapeutic, diagnostic, and patient-safety technologies are evolving through 2035.
6. U.S. Hospital-at-Home Devices Market – By Clinical Application
6.1. Overview
6.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)
6.1.2. Cardiovascular and Heart Failure Care
6.1.2.1. Heart Failure Management
6.1.2.2. Hypertension Monitoring
6.1.2.3. Arrhythmia and ECG Monitoring
6.1.2.4. Post-Acute Cardiovascular Monitoring
6.1.3. Respiratory Disease Management
6.1.3.1. COPD Exacerbation
6.1.3.2. Pneumonia
6.1.3.3. Acute Hypoxemia Management
6.1.3.4. Other Acute Respiratory Conditions
6.1.4. Infectious Disease and Acute Medical Care
6.1.4.1. Cellulitis
6.1.4.2. Urinary Tract Infections
6.1.4.3. IV Antibiotic Therapy
6.1.4.4. Dehydration and Electrolyte Management
6.1.4.5. Other Acute Medical Conditions
6.1.5. Post-Surgical and Orthopedic Recovery
6.1.5.1. Post-Operative Monitoring
6.1.5.2. Orthopedic Recovery
6.1.5.3. Wound Monitoring
6.1.5.4. Post-Surgical Mobility Management
6.1.5.5. Early Supported Discharge
6.1.6. Complex Chronic, Metabolic, Renal and Oncology Care
6.1.6.1. Diabetes and Glycemic Management
6.1.6.2. Renal Disease Monitoring
6.1.6.3. Oncology Supportive Care
6.1.6.4. Multimorbidity Management
6.1.6.5. Other Complex Chronic Conditions
What this section provides: This section evaluates device demand by clinical use case and identifies the disease pathways most suitable for hospital-at-home expansion, including cardiovascular, respiratory, infectious disease, post-surgical, metabolic, renal, and complex chronic care.
7. U.S. Hospital-at-Home Devices Market – By Care Model
7.1. Overview
7.1.1. Segment Share Analysis, By Care Model, 2025 & 2035 (%)
7.1.2. Acute Inpatient Substitution
7.1.2.1. Emergency Department Diversion to Home
7.1.2.2. Direct Acute Admission to Home
7.1.2.3. Hospital-Level Home Admission Following ED Evaluation
7.1.3. Early Supported Discharge
7.1.3.1. Medical Early Discharge
7.1.3.2. Post-Procedure Early Discharge
7.1.3.3. Transitional High-Acuity Monitoring
7.1.4. High-Acuity Chronic Exacerbation Management
7.1.4.1. Heart Failure Exacerbation
7.1.4.2. COPD Exacerbation
7.1.4.3. Complex Diabetes and Metabolic Episodes
7.1.4.4. Other Chronic Disease Exacerbations
7.1.5. Post-Operative Virtual Wards
7.1.5.1. Orthopedic Virtual Wards
7.1.5.2. General Surgery Virtual Wards
7.1.5.3. Cardiovascular Post-Procedure Monitoring
7.1.5.4. Other Surgical Virtual Wards
7.1.6. Hybrid Hospital-at-Home Programs
7.1.6.1. Remote Command Center + Mobile Nursing
7.1.6.2. Remote Monitoring + Home Infusion
7.1.6.3. Virtual Physician + In-Home Diagnostics
7.1.6.4. Integrated Multi-Service Hospital-at-Home Programs
What this section provides: This section explains how device requirements differ across acute inpatient substitution, early discharge, chronic exacerbation management, virtual wards, and hybrid hospital-at-home models.
8. U.S. Hospital-at-Home Devices Market – By End User & Procurement Channel
8.1. Overview
8.1.1. Segment Share Analysis, By End User & Procurement Channel, 2025 & 2035 (%)
8.1.2. Hospitals and Integrated Health Systems
8.1.2.1. Direct Hospital Procurement
8.1.2.2. Integrated Delivery Network Enterprise Contracts
8.1.2.3. Group Purchasing Organization Contracts
8.1.2.4. Device Leasing and Managed Equipment Models
8.1.3. Hospital-at-Home Enablement and Technology Companies
8.1.3.1. Device-Integrated Enablement Contracts
8.1.3.2. Platform-Based Device Bundles
8.1.3.3. Per-Patient-Day Equipment Models
8.1.4. Home Infusion and Specialty Pharmacy Providers
8.1.4.1. Infusion Pump Procurement
8.1.4.2. Drug Delivery Equipment Procurement
8.1.4.3. Pharmacy-Integrated Device Programs
8.1.5. Durable Medical Equipment and Respiratory Providers
8.1.5.1. Oxygen and Respiratory Equipment
8.1.5.2. Mobility and Safety Equipment
8.1.5.3. Distributor-Based Device Deployment
8.1.6. Home Health, Mobile Clinical and Risk-Bearing Organizations
8.1.6.1. Home Health Agency Procurement
8.1.6.2. Mobile Physician and Nursing Organization Procurement
8.1.6.3. Medicare Advantage and Value-Based Care Organizations
8.1.6.4. Accountable Care and Population Health Organizations
What this section provides: This section shows who purchases hospital-at-home devices, how purchasing decisions are made, and how direct hospital contracting, IDN agreements, GPOs, enablement companies, infusion providers, DME suppliers, and risk-bearing organizations influence commercial access.
9. U.S. Hospital-at-Home Devices Market – By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Hospital-at-Home Program Adoption Analysis
9.1.4. Regional Hospital Infrastructure and Acute-Care Capacity Analysis
9.1.5. Regional CMS Participation and Reimbursement Landscape
9.1.6. State Medicaid Hospital-at-Home Coverage Analysis
9.1.7. Regional Device Procurement and Logistics Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Hospital-at-Home Device Manufacturers and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.8. West Region Hospital-at-Home Adoption, Reimbursement and Commercial Opportunity Analysis
9.2.9. California
9.2.9.1. Overview
9.2.9.2. California Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.9.3. California Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.9.4. California Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.9.5. California Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.10. Washington
9.2.10.1. Overview
9.2.10.2. Washington Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.10.3. Washington Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.10.4. Washington Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.10.5. Washington Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.11.3. Arizona Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.11.4. Arizona Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.11.5. Arizona Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.12. Colorado
9.2.12.1. Overview
9.2.12.2. Colorado Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.12.3. Colorado Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.12.4. Colorado Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.12.5. Colorado Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.13. Oregon
9.2.13.1. Overview
9.2.13.2. Oregon Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.13.3. Oregon Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.13.4. Oregon Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.13.5. Oregon Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.14.3. Utah Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.14.4. Utah Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.14.5. Utah Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.15. Nevada
9.2.15.1. Overview
9.2.15.2. Nevada Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.15.3. Nevada Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.15.4. Nevada Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.15.5. Nevada Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.16. New Mexico
9.2.16.1. Overview
9.2.16.2. New Mexico Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.16.3. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.16.4. New Mexico Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.16.5. New Mexico Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.17. Idaho
9.2.17.1. Overview
9.2.17.2. Idaho Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.17.3. Idaho Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.17.4. Idaho Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.17.5. Idaho Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.18. Montana
9.2.18.1. Overview
9.2.18.2. Montana Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.18.3. Montana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.18.4. Montana Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.18.5. Montana Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.19. Wyoming
9.2.19.1. Overview
9.2.19.2. Wyoming Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.19.3. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.19.4. Wyoming Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.19.5. Wyoming Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.20. Alaska
9.2.20.1. Overview
9.2.20.2. Alaska Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.20.3. Alaska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.20.4. Alaska Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.20.5. Alaska Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.2.21. Hawaii
9.2.21.1. Overview
9.2.21.2. Hawaii Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.2.21.3. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.2.21.4. Hawaii Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.2.21.5. Hawaii Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Hospital-at-Home Device Manufacturers and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.8. Northeast Region Hospital-at-Home Adoption, Reimbursement and Commercial Opportunity Analysis
9.3.9. New York
9.3.9.1. Overview
9.3.9.2. New York Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.9.3. New York Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.9.4. New York Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.9.5. New York Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.10. Massachusetts
9.3.10.1. Overview
9.3.10.2. Massachusetts Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.10.3. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.10.4. Massachusetts Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.10.5. Massachusetts Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.11. New Jersey
9.3.11.1. Overview
9.3.11.2. New Jersey Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.11.3. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.11.4. New Jersey Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.11.5. New Jersey Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.12. Pennsylvania
9.3.12.1. Overview
9.3.12.2. Pennsylvania Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.12.3. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.12.4. Pennsylvania Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.12.5. Pennsylvania Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.13. Connecticut
9.3.13.1. Overview
9.3.13.2. Connecticut Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.13.3. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.13.4. Connecticut Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.13.5. Connecticut Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.14. Maine
9.3.14.1. Overview
9.3.14.2. Maine Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.14.3. Maine Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.14.4. Maine Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.14.5. Maine Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.15. Vermont
9.3.15.1. Overview
9.3.15.2. Vermont Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.15.3. Vermont Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.15.4. Vermont Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.15.5. Vermont Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.16. New Hampshire
9.3.16.1. Overview
9.3.16.2. New Hampshire Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.16.3. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.16.4. New Hampshire Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.16.5. New Hampshire Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.17. Rhode Island
9.3.17.1. Overview
9.3.17.2. Rhode Island Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.17.3. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.17.4. Rhode Island Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.17.5. Rhode Island Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.3.18. Delaware
9.3.18.1. Overview
9.3.18.2. Delaware Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.3.18.3. Delaware Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.3.18.4. Delaware Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.3.18.5. Delaware Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Hospital-at-Home Device Manufacturers and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.8. South Region Hospital-at-Home Adoption, Reimbursement and Commercial Opportunity Analysis
9.4.9. Texas
9.4.9.1. Overview
9.4.9.2. Texas Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.9.3. Texas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.9.4. Texas Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.9.5. Texas Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.10. Florida
9.4.10.1. Overview
9.4.10.2. Florida Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.10.3. Florida Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.10.4. Florida Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.10.5. Florida Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.11. Georgia
9.4.11.1. Overview
9.4.11.2. Georgia Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.11.3. Georgia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.11.4. Georgia Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.11.5. Georgia Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.12. North Carolina
9.4.12.1. Overview
9.4.12.2. North Carolina Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.12.3. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.12.4. North Carolina Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.12.5. North Carolina Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.13. Tennessee
9.4.13.1. Overview
9.4.13.2. Tennessee Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.13.3. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.13.4. Tennessee Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.13.5. Tennessee Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.14. South Carolina
9.4.14.1. Overview
9.4.14.2. South Carolina Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.14.3. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.14.4. South Carolina Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.14.5. South Carolina Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.15. Alabama
9.4.15.1. Overview
9.4.15.2. Alabama Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.15.3. Alabama Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.15.4. Alabama Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.15.5. Alabama Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.16. Mississippi
9.4.16.1. Overview
9.4.16.2. Mississippi Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.16.3. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.16.4. Mississippi Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.16.5. Mississippi Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.17. Louisiana
9.4.17.1. Overview
9.4.17.2. Louisiana Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.17.3. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.17.4. Louisiana Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.17.5. Louisiana Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.18. Arkansas
9.4.18.1. Overview
9.4.18.2. Arkansas Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.18.3. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.18.4. Arkansas Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.18.5. Arkansas Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.19. Kentucky
9.4.19.1. Overview
9.4.19.2. Kentucky Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.19.3. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.19.4. Kentucky Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.19.5. Kentucky Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.20. Oklahoma
9.4.20.1. Overview
9.4.20.2. Oklahoma Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.20.3. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.20.4. Oklahoma Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.20.5. Oklahoma Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.21. Virginia
9.4.21.1. Overview
9.4.21.2. Virginia Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.21.3. Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.21.4. Virginia Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.21.5. Virginia Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.22. Maryland
9.4.22.1. Overview
9.4.22.2. Maryland Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.22.3. Maryland Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.22.4. Maryland Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.22.5. Maryland Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.4.23. West Virginia
9.4.23.1. Overview
9.4.23.2. West Virginia Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.4.23.3. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.4.23.4. West Virginia Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.4.23.5. West Virginia Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Hospital-at-Home Device Manufacturers and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.8. Midwest Region Hospital-at-Home Adoption, Reimbursement and Commercial Opportunity Analysis
9.5.9. Illinois
9.5.9.1. Overview
9.5.9.2. Illinois Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.9.3. Illinois Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.9.4. Illinois Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.9.5. Illinois Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.10. Ohio
9.5.10.1. Overview
9.5.10.2. Ohio Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.10.3. Ohio Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.10.4. Ohio Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.10.5. Ohio Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.11. Michigan
9.5.11.1. Overview
9.5.11.2. Michigan Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.11.3. Michigan Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.11.4. Michigan Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.11.5. Michigan Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.12. Minnesota
9.5.12.1. Overview
9.5.12.2. Minnesota Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.12.3. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.12.4. Minnesota Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.12.5. Minnesota Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.13. Indiana
9.5.13.1. Overview
9.5.13.2. Indiana Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.13.3. Indiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.13.4. Indiana Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.13.5. Indiana Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.14. Wisconsin
9.5.14.1. Overview
9.5.14.2. Wisconsin Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.14.3. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.14.4. Wisconsin Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.14.5. Wisconsin Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.15. Missouri
9.5.15.1. Overview
9.5.15.2. Missouri Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.15.3. Missouri Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.15.4. Missouri Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.15.5. Missouri Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.16. Iowa
9.5.16.1. Overview
9.5.16.2. Iowa Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.16.3. Iowa Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.16.4. Iowa Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.16.5. Iowa Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.17. Kansas
9.5.17.1. Overview
9.5.17.2. Kansas Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.17.3. Kansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.17.4. Kansas Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.17.5. Kansas Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.18. Nebraska
9.5.18.1. Overview
9.5.18.2. Nebraska Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.18.3. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.18.4. Nebraska Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.18.5. Nebraska Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.19. North Dakota
9.5.19.1. Overview
9.5.19.2. North Dakota Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.19.3. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.19.4. North Dakota Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.19.5. North Dakota Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
9.5.20. South Dakota
9.5.20.1. Overview
9.5.20.2. South Dakota Market Size and Forecast, By Device Type, 2021–2035 (US$ Billion)
9.5.20.3. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
9.5.20.4. South Dakota Market Size and Forecast, By Care Model, 2021–2035 (US$ Billion)
9.5.20.5. South Dakota Market Size and Forecast, By End User & Procurement Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers comprehensive regional and state-level analysis across all 50 states, allowing clients to identify hospital-at-home adoption hotspots, reimbursement-friendly markets, health-system procurement opportunities, device-demand clusters, and state-level commercial priorities.
10. U.S. Hospital-at-Home Devices Market: Competitive Landscape & Company Profiles
10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking Analysis
10.2.1. Product Portfolio Breadth
10.2.2. Hospital and IDN Relationships
10.2.3. Connectivity and Interoperability Capability
10.2.4. Clinical Evidence
10.2.5. Home-Use Device Portfolio
10.2.6. Service and Logistics Capability
10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players
10.4. Company Profiles
10.4.1. Philips
10.4.2. GE HealthCare
10.4.3. Medtronic
10.4.4. Abbott Laboratories
10.4.5. Baxter International
10.4.6. Masimo
10.4.7. ResMed
10.4.8. Becton, Dickinson and Company
10.4.9. B. Braun
10.4.10. ICU Medical
10.4.11. Dexcom
10.4.12. Insulet Corporation
10.4.13. iRhythm Technologies
10.4.14. Boston Scientific Corporation
10.4.15. ZOLL Medical
10.4.16. BioIntelliSense
10.4.17. VitalConnect
10.4.18. Current Health / Best Buy Health
10.4.19. TytoCare
10.4.20. AliveCor
10.4.21. Eko Health
10.4.22. Withings Health Solutions
10.4.23. Fisher & Paykel Healthcare
10.4.24. OMRON Healthcare
Note: Each company profile will include company overview, relevant hospital-at-home device portfolio, U.S. market strategy, product positioning, clinical and technological capabilities, regulatory developments, partnerships, hospital collaborations, recent developments, and strategic outlook.
What this section provides: This section provides competitive benchmarking, company positioning, product-portfolio intelligence, hospital-at-home capabilities, innovation direction, and strategic assessment of the leading companies participating in the U.S. market.
11. U.S. Hospital-at-Home Devices Market: Recent Developments & Policy Evolution
11.1. Major Market Developments, 2024–2026
11.2. CMS Acute Hospital Care at Home Program Developments
11.3. Federal Hospital-at-Home Reimbursement Extension and Policy Outlook
11.4. State Medicaid Coverage Developments
11.5. FDA Home as a Health Care Hub Initiative
11.6. READI-Home and Home-Use Device Innovation
11.7. Recent Product Launches and FDA Clearances
11.8. Strategic Partnerships and Hospital Collaborations
11.9. Mergers, Acquisitions and Portfolio Expansion
11.10. Remote Monitoring and Biosensor Developments
11.11. Connected Infusion and Drug-Delivery Developments
11.12. Portable Diagnostic Device Developments
11.13. Hospital-at-Home Enablement Ecosystem Developments
What this section provides: This section tracks the most commercially relevant policy changes, regulatory initiatives, partnerships, product innovations, hospital deployments, and competitive developments reshaping hospital-at-home device demand.
12. U.S. Hospital-at-Home Devices Market: Future Market Outlook, 2026–2035
12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Continuous Wearable Biosensors
12.2.2. AI-Assisted Patient Deterioration Prediction
12.2.3. Portable Point-of-Care Diagnostics
12.2.4. Connected Infusion and Medication Delivery
12.2.5. Smart Respiratory Support Technologies
12.2.6. Virtual Examination Devices
12.2.7. Ambient and Contactless Monitoring
12.2.8. Connected Medical Device Hubs
12.3. Evolution of the Virtual Bed Model
12.4. Expansion into Higher-Acuity Patient Populations
12.5. Device Interoperability and Platform Consolidation
12.6. Emerging Commercial Models
12.6.1. Device-as-a-Service
12.6.2. Per-Patient-Day Pricing
12.6.3. Bundled Device Kits
12.6.4. Managed Device Logistics
12.6.5. Outcome-Linked Contracting
12.7. Emerging Business Trends
12.8. Business Opportunities for Startups and Existing Players
12.9. Investment Prioritization Matrix
12.10. Market White-Space Analysis
12.11. Technology Adoption Roadmap, 2026–2035
What this section provides: This section prepares clients for future care-model shifts, disruptive technologies, evolving commercial models, higher-acuity home treatment, emerging investment opportunities, and alternative market-growth scenarios through 2035.
13. U.S. Hospital-at-Home Devices Market: Strategic Recommendations
13.1. Recommendations for Medical Device Manufacturers
13.2. Recommendations for Remote Monitoring Companies
13.3. Recommendations for Hospitals and Integrated Health Systems
13.4. Recommendations for Hospital-at-Home Enablement Companies
13.5. Recommendations for Home Infusion and DME Providers
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for New Entrants and Startups
13.9. Go-to-Market Strategy Considerations
13.9.1. Enterprise Hospital Sales Strategy
13.9.2. IDN and GPO Contracting Strategy
13.9.3. Hospital-at-Home Enablement Partnerships
13.9.4. DME and Home Infusion Channel Partnerships
13.9.5. State-Level Market Prioritization
13.10. Product Positioning and Portfolio Expansion Guidance
13.11. Evidence Generation and Health-Economic Strategy
13.12. Reimbursement and Market Access Strategy
13.13. Device Interoperability Strategy
13.14. Device Logistics and Service Strategy
13.15. M&A and Partnership Opportunity Assessment
What this section provides: This section converts market intelligence into actionable strategic recommendations for product development, hospital contracting, reimbursement planning, geographic expansion, investment decisions, partnerships, channel development, and competitive differentiation.
14. U.S. Hospital-at-Home Devices Market: Disclaimer
14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. Market Sizing Limitation
14.5. Forecasting Limitation
14.6. Regulatory and Reimbursement Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s scope, market-definition boundaries, data limitations, forecasting assumptions, regulatory considerations, legal boundaries, and third-party data-use terms.
List of Tables
TABLE 1: List of Data Sources
TABLE 2: U.S. Hospital-at-Home Devices Market: Market Definition and Scope
TABLE 3: U.S. Hospital-at-Home Devices Market: Research Methodology Framework
TABLE 4: U.S. Hospital-at-Home Devices Market: Key Assumptions
TABLE 5: U.S. Hospital-at-Home Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Hospital-at-Home Devices Market: Stakeholder Analysis
TABLE 7: U.S. Hospital-at-Home Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Hospital-at-Home Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Hospital-at-Home Devices Market: Market Attractiveness Index
TABLE 10: U.S. Hospital-at-Home Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Hospital-at-Home Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Hospital-at-Home Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Hospital-at-Home Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Hospital-at-Home Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Hospital-at-Home Devices Market: Hospital-at-Home Adoption and Participation Snapshot
TABLE 16: U.S. Hospital-at-Home Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. Hospital-at-Home Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. Hospital-at-Home Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. Hospital-at-Home Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. Hospital-at-Home Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. Hospital-at-Home Devices Market: Clinical Workflow Economics Matrix
TABLE 22: U.S. Hospital-at-Home Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 23: U.S. Hospital-at-Home Devices Market: Inpatient Bed Substitution Economics
TABLE 24: U.S. Hospital-at-Home Devices Market: Cost-per-Episode and Device Utilization Analysis
TABLE 25: U.S. Hospital-at-Home Devices Market: Patient Selection and Clinical Escalation Framework
TABLE 26: U.S. Hospital-at-Home Devices Market: PESTEL Analysis
TABLE 27: U.S. Hospital-at-Home Devices Market: Porter’s Five Forces Analysis
TABLE 28: U.S. Hospital-at-Home Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. Hospital-at-Home Devices Market: Value Chain Analysis
TABLE 30: U.S. Hospital-at-Home Devices Market: Supply Chain Analysis
TABLE 31: U.S. Hospital-at-Home Devices Market: Digitalization and Connected Acute Home Care Impact
TABLE 32: U.S. Hospital-at-Home Devices Market: Application & Innovation Landscape
TABLE 33: U.S. Hospital-at-Home Devices Market: FDA Regulatory Framework Analysis
TABLE 34: U.S. Hospital-at-Home Devices Market: CMS Acute Hospital Care at Home Framework
TABLE 35: U.S. Hospital-at-Home Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 36: U.S. Hospital-at-Home Devices Market: State Medicaid Hospital-at-Home Coverage Landscape
TABLE 37: U.S. Hospital-at-Home Devices Market: Commercial Payer and Medicare Advantage Coverage Trends
TABLE 38: U.S. Hospital-at-Home Devices Market: FDA Home as a Health Care Hub Initiative
TABLE 39: U.S. Hospital-at-Home Devices Market: Medical Device Cybersecurity Requirements
TABLE 40: U.S. Hospital-at-Home Devices Market: Interoperability and EHR Integration Landscape
TABLE 41: U.S. Hospital-at-Home Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 42: U.S. Hospital-at-Home Devices Market: Government Initiatives Supporting Home-Based Care
TABLE 43: U.S. Hospital-at-Home Devices Market: Impact of Escalating Geopolitical and Supply-Chain Tensions
TABLE 44: U.S. Hospital-at-Home Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 45: U.S. Hospital-at-Home Devices Market: Device Fleet Management and Utilization Economics
TABLE 46: U.S. Hospital-at-Home Devices Market: Device Type Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Device Type
TABLE 48: U.S. Hospital-at-Home Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 49: U.S. Hospital-at-Home Devices Market: Segment Share Analysis, by Device Type, 2025 & 2035 (%)
TABLE 50: U.S. Hospital-at-Home Devices Market: Multiparameter and Continuous Patient Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Hospital-at-Home Devices Market: Therapeutic and Drug-Delivery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Hospital-at-Home Devices Market: Respiratory Support and Oxygen Therapy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Hospital-at-Home Devices Market: Point-of-Care Diagnostic and Examination Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Hospital-at-Home Devices Market: Mobility, Safety and Connected Support Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Hospital-at-Home Devices Market: Clinical Application Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 57: U.S. Hospital-at-Home Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 58: U.S. Hospital-at-Home Devices Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 59: U.S. Hospital-at-Home Devices Market: Cardiovascular and Heart Failure Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Hospital-at-Home Devices Market: Respiratory Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Hospital-at-Home Devices Market: Infectious Disease and Acute Medical Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Hospital-at-Home Devices Market: Post-Surgical and Orthopedic Recovery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Hospital-at-Home Devices Market: Complex Chronic, Metabolic, Renal and Oncology Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Hospital-at-Home Devices Market: Care Model Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Care Model
TABLE 66: U.S. Hospital-at-Home Devices Market, by Care Model, 2021–2035 (US$ Billion)
TABLE 67: U.S. Hospital-at-Home Devices Market: Segment Share Analysis, by Care Model, 2025 & 2035 (%)
TABLE 68: U.S. Hospital-at-Home Devices Market: Acute Inpatient Substitution Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Hospital-at-Home Devices Market: Early Supported Discharge Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Hospital-at-Home Devices Market: High-Acuity Chronic Exacerbation Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Hospital-at-Home Devices Market: Post-Operative Virtual Wards Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Hospital-at-Home Devices Market: Hybrid Hospital-at-Home Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Hospital-at-Home Devices Market: End User & Procurement Channel Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by End User & Procurement Channel
TABLE 75: U.S. Hospital-at-Home Devices Market, by End User & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 76: U.S. Hospital-at-Home Devices Market: Segment Share Analysis, by End User & Procurement Channel, 2025 & 2035 (%)
TABLE 77: U.S. Hospital-at-Home Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Hospital-at-Home Devices Market: Hospital-at-Home Enablement and Technology Companies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Hospital-at-Home Devices Market: Home Infusion and Specialty Pharmacy Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Hospital-at-Home Devices Market: Durable Medical Equipment and Respiratory Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Hospital-at-Home Devices Market: Home Health, Mobile Clinical and Risk-Bearing Organizations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Hospital-at-Home Devices Market: Regional Snapshot, 2025
TABLE 83: Segment Dashboard; Definition and Scope, by Region
TABLE 84: U.S. Hospital-at-Home Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 85: U.S. Hospital-at-Home Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 86: U.S. Hospital-at-Home Devices Market: Hospital-at-Home Adoption Analysis by Region
TABLE 87: U.S. Hospital-at-Home Devices Market: CMS and State Medicaid Reimbursement Analysis by Region
TABLE 88: U.S. Hospital-at-Home Devices Market: Regional Device Procurement and Logistics Dynamics
TABLE 89: West Region U.S. Hospital-at-Home Devices Market: Regional Overview and Trends
TABLE 90: West Region U.S. Hospital-at-Home Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 91: West Region U.S. Hospital-at-Home Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Hospital-at-Home Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Hospital-at-Home Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Hospital-at-Home Devices Market, by Care Model, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Hospital-at-Home Devices Market, by End User & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 96: California Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Hospital-at-Home Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Hospital-at-Home Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 111: Northeast Region U.S. Hospital-at-Home Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Hospital-at-Home Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Hospital-at-Home Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Hospital-at-Home Devices Market, by Care Model, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Hospital-at-Home Devices Market, by End User & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 116: New York Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Hospital-at-Home Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. Hospital-at-Home Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 128: South Region U.S. Hospital-at-Home Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Hospital-at-Home Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Hospital-at-Home Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Hospital-at-Home Devices Market, by Care Model, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Hospital-at-Home Devices Market, by End User & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 133: Texas Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Florida Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Georgia Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: North Carolina Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Tennessee Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: South Carolina Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Alabama Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Mississippi Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Louisiana Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Arkansas Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Kentucky Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Oklahoma Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Virginia Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Maryland Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: West Virginia Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Hospital-at-Home Devices Market: Regional Overview and Trends
TABLE 149: Midwest Region U.S. Hospital-at-Home Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 150: Midwest Region U.S. Hospital-at-Home Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. Hospital-at-Home Devices Market, by Device Type, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. Hospital-at-Home Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Hospital-at-Home Devices Market, by Care Model, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Hospital-at-Home Devices Market, by End User & Procurement Channel, 2021–2035 (US$ Billion)
TABLE 155: Illinois Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Ohio Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Michigan Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Minnesota Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Indiana Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Wisconsin Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Missouri Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Iowa Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Kansas Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Nebraska Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: North Dakota Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: South Dakota Hospital-at-Home Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: U.S. Hospital-at-Home Devices Market: Competitive Landscape Snapshot, 2025
TABLE 168: U.S. Hospital-at-Home Devices Market: Key Company Market Share Analysis, 2025
TABLE 169: U.S. Hospital-at-Home Devices Market: Company Positioning Matrix
TABLE 170: U.S. Hospital-at-Home Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 171: U.S. Hospital-at-Home Devices Market: Hospital-at-Home Capability Benchmarking
TABLE 172: U.S. Hospital-at-Home Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 173: Philips: Company Profile
TABLE 174: GE HealthCare: Company Profile
TABLE 175: Medtronic: Company Profile
TABLE 176: Abbott Laboratories: Company Profile
TABLE 177: Baxter International: Company Profile
TABLE 178: Masimo: Company Profile
TABLE 179: ResMed: Company Profile
TABLE 180: Becton, Dickinson and Company: Company Profile
TABLE 181: B. Braun: Company Profile
TABLE 182: ICU Medical: Company Profile
TABLE 183: Dexcom: Company Profile
TABLE 184: Insulet Corporation: Company Profile
TABLE 185: iRhythm Technologies: Company Profile
TABLE 186: Boston Scientific Corporation: Company Profile
TABLE 187: ZOLL Medical: Company Profile
TABLE 188: BioIntelliSense: Company Profile
TABLE 189: VitalConnect: Company Profile
TABLE 190: Current Health / Best Buy Health: Company Profile
TABLE 191: TytoCare: Company Profile
TABLE 192: AliveCor: Company Profile
TABLE 193: Eko Health: Company Profile
TABLE 194: Withings Health Solutions: Company Profile
TABLE 195: Fisher & Paykel Healthcare: Company Profile
TABLE 196: OMRON Healthcare: Company Profile
TABLE 197: U.S. Hospital-at-Home Devices Market: Recent Policy and Regulatory Developments, 2024–2026
TABLE 198: U.S. Hospital-at-Home Devices Market: CMS Acute Hospital Care at Home Developments
TABLE 199: U.S. Hospital-at-Home Devices Market: Federal Reimbursement Extension and Policy Outlook
TABLE 200: U.S. Hospital-at-Home Devices Market: State Medicaid Coverage Developments
TABLE 201: U.S. Hospital-at-Home Devices Market: FDA Home as a Health Care Hub and READI-Home Developments
TABLE 202: U.S. Hospital-at-Home Devices Market: Recent Product Launches and FDA Clearances
TABLE 203: U.S. Hospital-at-Home Devices Market: Strategic Partnerships and Hospital Collaborations
TABLE 204: U.S. Hospital-at-Home Devices Market: Connected Monitoring, Infusion and Portable Diagnostics Developments
TABLE 205: U.S. Hospital-at-Home Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 206: U.S. Hospital-at-Home Devices Market: Disruptive Technologies Impact Matrix
TABLE 207: U.S. Hospital-at-Home Devices Market: Virtual Bed Model Evolution
TABLE 208: U.S. Hospital-at-Home Devices Market: Higher-Acuity Patient Expansion Opportunity
TABLE 209: U.S. Hospital-at-Home Devices Market: Device Interoperability and Platform Consolidation
TABLE 210: U.S. Hospital-at-Home Devices Market: Emerging Commercial Models
TABLE 211: U.S. Hospital-at-Home Devices Market: Emerging Business Trends
TABLE 212: U.S. Hospital-at-Home Devices Market: Business Opportunities for Startups and Existing Players
TABLE 213: U.S. Hospital-at-Home Devices Market: Investment Prioritization Matrix
TABLE 214: U.S. Hospital-at-Home Devices Market: Market White-Space Analysis
TABLE 215: U.S. Hospital-at-Home Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 216: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Medical Device Manufacturers
TABLE 217: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Remote Monitoring Companies
TABLE 218: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 219: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Hospital-at-Home Enablement Companies
TABLE 220: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Home Infusion and DME Providers
TABLE 221: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 222: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 223: U.S. Hospital-at-Home Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 224: U.S. Hospital-at-Home Devices Market: Go-to-Market Strategy Considerations
TABLE 225: U.S. Hospital-at-Home Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 226: U.S. Hospital-at-Home Devices Market: Evidence Generation and Health-Economic Strategy
TABLE 227: U.S. Hospital-at-Home Devices Market: Reimbursement and Market Access Strategy
TABLE 228: U.S. Hospital-at-Home Devices Market: Device Interoperability Strategy
TABLE 229: U.S. Hospital-at-Home Devices Market: Device Logistics and Service Strategy
TABLE 230: U.S. Hospital-at-Home Devices Market: M&A and Partnership Opportunity Assessment
TABLE 231: U.S. Hospital-at-Home Devices Market: Scope Limitation
TABLE 232: U.S. Hospital-at-Home Devices Market: Market Definition Limitation
TABLE 233: U.S. Hospital-at-Home Devices Market: Data Use Limitation
TABLE 234: U.S. Hospital-at-Home Devices Market: Market Sizing Limitation
TABLE 235: U.S. Hospital-at-Home Devices Market: Forecasting Limitation
TABLE 236: U.S. Hospital-at-Home Devices Market: Regulatory and Reimbursement Limitation
TABLE 237: U.S. Hospital-at-Home Devices Market: Legal Disclaimer
TABLE 238: U.S. Hospital-at-Home Devices Market: Third-Party Data Disclaimer
List of Figures
FIGURE 1: U.S. Hospital-at-Home Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem Overview
FIGURE 4: Stakeholder Ecosystem
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Hospital-at-Home Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Hospital-at-Home Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Hospital-at-Home Adoption and Participation Trend
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Workflow Economics Framework
FIGURE 13: Hospital Capital Procurement Decision Framework
FIGURE 14: Inpatient Bed Substitution Economics Framework
FIGURE 15: Cost-per-Episode and Device Utilization Framework
FIGURE 16: Patient Selection and Clinical Escalation Framework
FIGURE 17: PESTEL Analysis
FIGURE 18: Porter’s Five Forces Analysis
FIGURE 19: Value Chain Analysis
FIGURE 20: Supply Chain Analysis
FIGURE 21: Regulatory and Reimbursement Landscape
FIGURE 22: Medical Device Cybersecurity and Interoperability Framework
FIGURE 23: Device Fleet Management and Utilization Framework
FIGURE 24: Device Type Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Device Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Multiparameter and Continuous Patient Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Therapeutic and Drug-Delivery Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Respiratory Support and Oxygen Therapy Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Point-of-Care Diagnostic and Examination Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Mobility, Safety and Connected Support Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Cardiovascular and Heart Failure Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Respiratory Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Infectious Disease and Acute Medical Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Post-Surgical and Orthopedic Recovery Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Complex Chronic, Metabolic, Renal and Oncology Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Care Model Segment Market Share Analysis, 2025 & 2035
FIGURE 39: Care Model Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Acute Inpatient Substitution Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Early Supported Discharge Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: High-Acuity Chronic Exacerbation Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Post-Operative Virtual Wards Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Hybrid Hospital-at-Home Programs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: End User & Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: End User & Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Hospital-at-Home Enablement and Technology Companies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Home Infusion and Specialty Pharmacy Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Durable Medical Equipment and Respiratory Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Home Health, Mobile Clinical and Risk-Bearing Organizations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Regional Hospital-at-Home Adoption and Reimbursement Opportunity Map
FIGURE 55: West Region U.S. Hospital-at-Home Devices Market Share and Leading Players, 2025
FIGURE 56: West Region Market Share Analysis by State, 2025
FIGURE 57: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: California Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Washington Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Arizona Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Colorado Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Oregon Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Utah Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Nevada Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: New Mexico Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Idaho Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Montana Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Wyoming Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Alaska Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Hawaii Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Northeast Region U.S. Hospital-at-Home Devices Market Share and Leading Players, 2025
FIGURE 72: Northeast Region Market Share Analysis by State, 2025
FIGURE 73: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: New York Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Massachusetts Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New Jersey Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Pennsylvania Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Connecticut Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Maine Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Vermont Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: New Hampshire Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Rhode Island Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Delaware Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: South Region U.S. Hospital-at-Home Devices Market Share and Leading Players, 2025
FIGURE 85: South Region Market Share Analysis by State, 2025
FIGURE 86: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Texas Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Florida Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Georgia Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: North Carolina Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Tennessee Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: South Carolina Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Alabama Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Mississippi Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Louisiana Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Arkansas Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Kentucky Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Oklahoma Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Virginia Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Maryland Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: West Virginia Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Midwest Region U.S. Hospital-at-Home Devices Market Share and Leading Players, 2025
FIGURE 103: Midwest Region Market Share Analysis by State, 2025
FIGURE 104: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Illinois Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Ohio Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Michigan Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Minnesota Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Indiana Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Wisconsin Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Missouri Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Iowa Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Kansas Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Nebraska Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: North Dakota Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: South Dakota Hospital-at-Home Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 118: Company Positioning Matrix
FIGURE 119: Key Player Product Portfolio Benchmarking
FIGURE 120: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 121: Hospital-at-Home Device Innovation Roadmap
FIGURE 122: Policy and Regulatory Evolution, 2024–2026
FIGURE 123: CMS Acute Hospital Care at Home and Reimbursement Timeline
FIGURE 124: FDA Home as a Health Care Hub and READI-Home Innovation Roadmap
FIGURE 125: Recent Hospital-at-Home Device Ecosystem Developments
FIGURE 126: Future Market Scenario Analysis, 2026–2035
FIGURE 127: Disruptive Technologies Impact Matrix
FIGURE 128: Virtual Bed Model Evolution Roadmap
FIGURE 129: Higher-Acuity Home Care Opportunity Map
FIGURE 130: Emerging Commercial Models Matrix
FIGURE 131: Market White-Space Opportunity Map
FIGURE 132: Technology Adoption Roadmap, 2026–2035
FIGURE 133: Strategic Growth Roadmap for U.S. Hospital-at-Home Device Companies
FIGURE 134: Go-to-Market Strategy Framework
FIGURE 135: Product Positioning and Portfolio Expansion Framework
FIGURE 136: Evidence Generation and Reimbursement Strategy Framework
FIGURE 137: Channel, Device Logistics and Service Strategy Framework
FIGURE 138: Report Scope and Disclaimer Framework